Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Emerging oral agents for multiple sclerosis.
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Teriflunomide for multiple sclerosis.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Rituximab (marketed as Rituxan), Information
Risks of immune system treatments.
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Current and future immunotherapy targets in autoimmune neurology.
Information for healthcare professionals: Rituximab
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Extension CombiRx data show no benefit of combined MS drugs
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)

Pages